Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers Meeting Abstract
| Authors: | Fernandez, E. E.; Garralda, E.; Parikh, A.; Italiano, A.; Hollebecque, A.; Marabelle, A.; Friedman, C.; Sullivan, R.; Tschernia, N.; Juarez, M. M. H.; He, K.; Bilusic, M.; Trujillo, M. P.; Su, Z.; Liu, K.; Kopetz, S.; Gulle, J.; Siu, L. L.; Ducreux, M. P.; Tabernero, J. |
| Abstract Title: | Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers |
| Meeting Title: | ESMO Gastrointestinal Cancers Congress Congress 2025 |
| Journal Title: | Annals of Oncology |
| Volume: | 36 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2025 Jul 2-5 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2025-07-01 |
| Start Page: | S181 |
| Language: | English |
| ACCESSION: | WOS:001545624000131 |
| DOI: | 10.1016/j.annonc.2025.05.496 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 479MO -- Source: Wos |
